CN111328420B - 用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗 - Google Patents

用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗 Download PDF

Info

Publication number
CN111328420B
CN111328420B CN201880046801.8A CN201880046801A CN111328420B CN 111328420 B CN111328420 B CN 111328420B CN 201880046801 A CN201880046801 A CN 201880046801A CN 111328420 B CN111328420 B CN 111328420B
Authority
CN
China
Prior art keywords
frameshift
cancer
peptides
peptide
collection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880046801.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111328420A (zh
Inventor
阿尔弗雷多·尼科西亚
埃莉萨·斯卡尔塞利
圭多·莱昂尼
阿明·拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nouscom AG
Original Assignee
Nouscom AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom AG filed Critical Nouscom AG
Publication of CN111328420A publication Critical patent/CN111328420A/zh
Application granted granted Critical
Publication of CN111328420B publication Critical patent/CN111328420B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880046801.8A 2017-07-12 2018-07-12 用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗 Active CN111328420B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17181026.0 2017-07-12
EP17181026 2017-07-12
PCT/EP2018/069032 WO2019012082A1 (en) 2017-07-12 2018-07-12 UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)

Publications (2)

Publication Number Publication Date
CN111328420A CN111328420A (zh) 2020-06-23
CN111328420B true CN111328420B (zh) 2023-07-25

Family

ID=59366234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880046801.8A Active CN111328420B (zh) 2017-07-12 2018-07-12 用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗

Country Status (19)

Country Link
US (1) US11578109B2 (enExample)
EP (1) EP3652606B1 (enExample)
JP (1) JP7274223B2 (enExample)
KR (1) KR102709778B1 (enExample)
CN (1) CN111328420B (enExample)
AU (1) AU2018298849B2 (enExample)
BR (1) BR112020000590A2 (enExample)
CA (1) CA3069047A1 (enExample)
DK (1) DK3652606T5 (enExample)
ES (1) ES2940087T3 (enExample)
FI (1) FI3652606T3 (enExample)
HU (1) HUE061840T2 (enExample)
IL (1) IL271966B2 (enExample)
MX (1) MX2020000413A (enExample)
NZ (1) NZ759940A (enExample)
PL (1) PL3652606T3 (enExample)
PT (1) PT3652606T (enExample)
SG (1) SG11202000250PA (enExample)
WO (1) WO2019012082A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827263A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
WO2020022903A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
CA3106567A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
EP3827261A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
US20210187088A1 (en) 2018-07-26 2021-06-24 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220008525A1 (en) * 2019-02-07 2022-01-13 Arizona Board Of Regents On Behalf Of Arizona State University Cancer specific frameshift vaccines
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
WO2021228999A1 (en) * 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2024516542A (ja) * 2021-04-06 2024-04-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍｈｃクラスｉペプチドを含む方法および組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102850434A (zh) * 2006-10-17 2013-01-02 肿瘤疗法科学股份有限公司 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN102947325A (zh) * 2010-04-09 2013-02-27 肿瘤疗法科学股份有限公司 Cdca5肽及包含它们的疫苗
CN103732743A (zh) * 2011-08-12 2014-04-16 肿瘤疗法科学股份有限公司 Mphosph1肽及包含它们的疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
WO2003087162A2 (en) * 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
US20060160090A1 (en) * 2003-04-11 2006-07-20 Macina Robert A Composition splice variants and methods relating to cancer specific genes and proteins
CN1824325A (zh) * 2005-12-16 2006-08-30 武汉大学 人乳头病毒dna嵌合疫苗及制备方法和应用
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
SG175407A1 (en) 2009-05-29 2011-11-28 Morphosys Ag A collection and methods for its use
CA2830787C (en) * 2011-03-24 2019-11-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dominant negative hsp110 mutant and its use in prognosing and treating cancers
BR112015013737B1 (pt) * 2012-12-13 2021-07-27 Ruprecht-Karls-Universitãt Heidelberg Peptídeos com alteração do quadro de leitura msiespecífico (fsp) para a prevenção e tratamento do câncer
US9205140B2 (en) * 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
WO2014099979A2 (en) * 2012-12-17 2014-06-26 Virginia Tech Intellectual Properties, Inc. Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
WO2015112930A1 (en) * 2014-01-27 2015-07-30 Yale University Novel methods of identifying patients responsive to immunotherapeutic strategies
IL302102A (en) 2015-05-20 2023-06-01 Dana Farber Cancer Inst Inc shared neoantigens
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
US12150980B2 (en) * 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102850434A (zh) * 2006-10-17 2013-01-02 肿瘤疗法科学股份有限公司 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN102947325A (zh) * 2010-04-09 2013-02-27 肿瘤疗法科学股份有限公司 Cdca5肽及包含它们的疫苗
CN103732743A (zh) * 2011-08-12 2014-04-16 肿瘤疗法科学股份有限公司 Mphosph1肽及包含它们的疫苗

Also Published As

Publication number Publication date
IL271966A (en) 2020-02-27
US20200222519A1 (en) 2020-07-16
FI3652606T3 (fi) 2023-03-16
KR102709778B1 (ko) 2024-09-26
BR112020000590A2 (pt) 2020-07-14
US11578109B2 (en) 2023-02-14
MX2020000413A (es) 2020-09-28
EP3652606B1 (en) 2023-01-11
JP7274223B2 (ja) 2023-05-16
RU2019144505A3 (enExample) 2021-08-12
HUE061840T2 (hu) 2023-08-28
WO2019012082A1 (en) 2019-01-17
IL271966B1 (en) 2024-09-01
RU2019144505A (ru) 2021-08-12
JP2020532288A (ja) 2020-11-12
IL271966B2 (en) 2025-01-01
AU2018298849B2 (en) 2022-07-14
EP3652606A1 (en) 2020-05-20
AU2018298849A1 (en) 2020-01-02
PT3652606T (pt) 2023-03-16
SG11202000250PA (en) 2020-02-27
CN111328420A (zh) 2020-06-23
CA3069047A1 (en) 2019-01-17
KR20200029443A (ko) 2020-03-18
NZ759940A (en) 2023-07-28
DK3652606T3 (da) 2023-03-13
PL3652606T3 (pl) 2023-04-24
DK3652606T5 (da) 2024-08-26
ES2940087T3 (es) 2023-05-03
WO2019012082A9 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
CN111328420B (zh) 用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗
AU2021232660B2 (en) HPV vaccines
RU2019119272A (ru) Вирусная доставка неоантигенов
JP2020530761A (ja) 非ヒト大型類人猿アデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
JP7551495B2 (ja) Ｈｐｖワクチン
JP2003509035A (ja) ポリエピトープポリペプチドをコードする核酸
JPH10504702A (ja) 免疫原製剤
CA3109541A1 (en) Teleost invariant chain cancer vaccine
EP4281110A2 (en) Modified alphavirus vectors
JP2007523610A (ja) 癌胎児抗原をコードする合成遺伝子およびその使用
US12295997B2 (en) Prostate neoantigens and their uses
US20240002879A1 (en) Gorilla adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
HK40029760A (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
HK40029760B (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
TWI901715B (zh) 大猩猩腺病毒核酸及胺基酸序列，包含彼之載體，及其用途
RU2808567C2 (ru) Противораковая вакцина с инвариантной цепью из костистых рыб
CN118302195A (zh) 泛冠状病毒疫苗
IL311439A (en) pancoronavirus vaccines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant